Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biotage Board/Management Information 2016

Jun 1, 2016

2894_rns_2016-06-01_4cfc48b4-f430-4575-9f43-5c1913d0c16e.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

Press release Biotage AB

Contact persons: SE-751 03 Uppsala Torben Jörgensen, CEO Tel:018 56 59 00 Tel: 0707-49 05 84, [email protected] www.biotage.com

Box 8

Uppsala June 1, 2016

Biotage AB (publ) – board member Anders Walldov leaves his assignments

Anders Walldov, member of the Board of Directors, sold his and with him related companies' entire shareholding in Biotage on 17 May 2016.

Anders Walldov will keep his assignments as a Board Member and a member of the Compensation Committee up and until the Board meeting on 10 August 2016. A new member of the Compensation Committee will be appointed at the forthcoming Board meeting.

The current Nomination Committee has not notified the company about any intention to suggest a new member of the Board of Directors in advance of convening the new Nomination Committee for the 2017 AGM.

Biotage discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 9 am CET on 1 June 2016.

About Biotage

Biotage offers efficient separation technologies from analysis to industrial scale and high quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage's products are used by government authorities, academic institutions, pharmaceutical and food companies, among others. The company is headquartered in Uppsala and has offices in the US, UK, China and Japan. Biotage has approx. 290 employees and had sales of 610 MSEK in 2015. Biotage is listed on the NASDAQ OMX Stockholm stock exchange. Website: www.biotage.com